# JC10 Rec'd PCT/PTO 0 1 JUN 2005

Form PTO 1390 (REV 5-93)	U.S. DEPARTMENT OF COM	IMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER P51394						
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371									
INTERNATIONAL PCT/US03/0	APPLICATION NO. 38444	INTERNATIONAL FILING DATE 03 December 2003	PRIORITY DATE CLAIMED 04 December 2002						
TITLE OF INVENTION QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS									
APPLICANT(S) FOR DO/EO/US  Jeffrey Michael AXTEN, Catherine Genevieve DARTOIS, Guy Marguerite Marie Gerard  NADLER and Neil David PEARSON									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
<ol> <li>[x] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>[] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>[x] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>[x] The US has been elected (Article 31).</li> </ol>									
a. [] b. [] c. [x]	c. [x] is not required, as the application was filed in the United States Receiving Office (RO/US).								
<ul> <li>6. [] A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7. [] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul> <li>a. [] are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. [] have been transmitted by the International Bureau.</li> <li>c. [] have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. [] have not been made and will not be made.</li> </ul> </li> </ul>									
		ne inventor(s) (35 U.S.C. 371(c)(4))							
	lation of the annexe 371(c)(5)).	s to the International Preliminary Ex	amination Report under PCT Article 36 (35						
11. [x] An Info 12. [] An assi and 3.3	rmation Disclosure gnment document for 1 is included.								
(Add of 14. [] A SECO 15. [] A subst 16. [] Power of 17. [x] An Abst 18. [x] Copy of 19. [x]	OND or SUBSEQU itute specification.	a Preliminary Amendment for US ENT preliminary amendment.  Sheet of paper.  O.	originating cases only)						

## JC18 Rec'd PCT/PTO 0 1 JUN 2005

US APPLICATION DO: 66 10 3 7 0 3 CER 1.50) INTERNATIONAL APPLICATION NO. PCT/US03/038444			ATTORNEYS DOCKET NO. P51394		
20. [X] The fo	llowing fees are submit	CALCULATION	PTO USE ONLY		
Basic	National Fee (37 C.F	.R. 1.492(a)(1)-(5)):			
■ Basic I	Filing Fee		\$300.00	\$300.00	
	nation Fee			-	
	nal Preliminary Examinati				
	isions of PCTArtlice33(1	\$200.00			
		<u></u>	\$200.00		
■ Search					
	37 CFR 1.445(a)(2) has b				
			\$100.00	\$100.00	
			ice\$400.00		
*All other situ	ations	4 400 00			
	pro-	\$600.00			
	0.00 for furnishing the	\$0.00			
	earliest claimed priorit				
Claims	Number Filed	Number Extra	Rate		
Total claims	9 - 20 =	0	0 x \$50.00	\$0.00	
Independent claims	1 - 3 =	0	0 x \$200.00	\$0.00	
	ent claims (if applicable	+ \$360.00	\$0.00		
		\$600.00			
National Stage A	pplication size fee - for	each additional 50 s	heets that exceed 100	\$0.00	
	0 addt'l sheets <u>1</u> x \$250				
		\$600.00			
	\$130.00 for furnishing	\$			
☐ 20 ☐ 30 mon	ths from the earliest cla				
		\$600.00			
		Amount to be	\$		
		refunded			
		charged	\$		

a. 🗀	A check in	the amount of \$	to cover	the above	fees is	enclosed.
------	------------	------------------	----------	-----------	---------	-----------

- b.  $\square$  Please charge my Deposit Account No. <u>19-2570</u> in the amount of <u>\$600.00</u> to cover the above fees.
- d. General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**GLAXOSMITHKLINE** 

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5629

Facsimile (610) 270-5090

**SIGNATURE** 

Chris P. Miller

NAME

55,852

REGISTRATION NO.

P. Mill

n:\cpm\cases\p51394\national stage.doc

# 10/537034

### JC20 Rec'd PCT/PTO 01 JUN 2005

**PATENT** 

ATTORNEY'S DOCKET NUMBER P51394

# TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO.

INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

PCT/US03/038444

03 December 2003

04 December 2002

TITLE OF INVENTION

QUINOLINES AND NITROGENATED DERIVATIVES THEREOF AND THEIR USE AS ANTIBACTERIAL AGENTS

APPLICANT(S) FOR DO/US

Jeffrey Michael AXTEN, Catherine Genevieve DARTOIS, Guy Marguerite Marie Gerard NADLER and Neil David PEARSON

Commissioner for Patents

Mail Stop: PCT P.O. Box 1450

Alexandria, VA 22313-1450 ATTENTION: DO/US

#### **CERTIFICATION UNDER 37 CFR 1.10**

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date <u>June 1, 2005</u> in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV608165506US addressed to the:

Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person/mailing paper)